The relatively high incidence of side effects, meaningful discontinuation rates even in RCTs, and the inherent complexity of obesity‐related HFpEF underscore the importance of a multidisciplinary approach, including HF specialists, nurses, nutritionists, endocrinologists and rehabilitation experts, to optimize GLP‐1 RA or GLP‐1/GIP RA therapy and ensure adherence. The gene discussed is GIP; the disease is obesity disorder.